Compare Tesla, Inc. (TSLA) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Tesla (TSLA) trades at $367.16, down 2.88% on the day, amid mixed signals. The technical outlook is bullish based on moving averages, but oscillators are neutral. Recent earnings showed a Q2 2026 miss after two prior beats. Revenue declined slightly in 2025 to $94.83B, with net income margin compressing to 4%. The company maintains a strong balance sheet with $36.56B in cash, though valuation ratios like a P/E of 347.44 remain elevated. News highlights focus on autonomous driving approvals in Europe and a potential cheaper EV model.

Tesla's investment case balances high growth expectations in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $441.36 implies upside, but investors face risks from competitive pressures, volatile earnings, and the stock's sensitivity to sentiment shifts around its AI and robotics initiatives.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.